EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer

Xiaojing Xu iD, Minzhi Lv iD, Luoyan Ai, Qing Wang, Yuehong Cui, Wei Li, Qing Liu, Xi Tang iD, Xi Chen, Shan Yu, Mengzhou Guo, Yiyi Yu und 1 weitere

The Oncologist · 07.10.2026 · 31 (11)

DOI: 10.1093/oncolo/oyag385 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 01.10.2026. Verfasst von Xiaojing Xu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antibodies, Monoclonal, Humanized, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSCO Clinical Oncology Research Foundation, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Nature Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Late-line treatment options for microsatellite stable (MSS)/proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC) are limited. PD-1 blockade alone has minimal clinical benefit in this population. Human epidermal growth factor receptor 2 (HER2)-targeted therapies represent an emerging strategy for HER2-expressing mCRC. This study evaluated the efficacy and safety of pembrolizumab combined with disitamab vedotin (DV), an anti-HER2 antibody–drug conjugate (ADC), in pretreated patients with HER2-positive mCRC.

Methods

This multicenter, single-arm, phase II study enrolled patients with MSS/pMMR, HER2-positive mCRC who received 2 prior lines of systemic therapy. Patients received pembrolizumab 400 mg every 6 weeks plus DV 2.5 mg/kg every 2 weeks until disease progression, unacceptable toxicity, or death. The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety.

Results

Between December 2022 and May 2024, 15 patients (median age 59.0 years; 60.0% male) were enrolled. Fourteen patients (93.3%) had HER2 IHC 3+ expressions, and 2 had received prior anti-HER2 therapy. Two patients achieved partial response (ORR = 13.3%; 95% CI, 1.7%-40.5%). With a median follow-up of 26.7 months, median PFS was 2.9 months (95% CI, 2.3 to not reached). Median OS was not reached (95% CI, 16.7 to NR). The 6-month OS rate was 92.9% (95% CI: 6.9%-80.3%), and the 1-year OS rate was 71.4% (95% CI: 51.3%-99.5%). The most common treatment-related adverse events (TRAEs) included nausea, anorexia, alanine aminotransferase elevation, aspartate aminotransferase elevation, and alopecia. Grade 3-4 TRAEs occurred in 2 patients (14.3%), both neutropenia.

Conclusions

Pembrolizumab plus disitamab vedotin showed limited antitumor activity in pretreated HER2-positive mCRC. ClinicalTrials.gov Identifier NCT05333809

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntibodies, Monoclonal, HumanizedErb-b2 Receptor Tyrosine KinasesAntineoplastic Combined Chemotherapy ProtocolsImmunoconjugatesHumansFemaleMaleMiddle AgedAgedAdultNeoplasm MetastasisAntibodies, MonoclonalOligopeptides

Stichwörter der Autor:innen

HER2disitamab vedotinmetastatic colorectal cancerpembrolizumab

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmunoconjugatesdisitamab vedotinAntibodies, MonoclonalOligopeptides

Autor:innen und Institutionen

  • Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Cancer Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Department of Cancer Screening and Prevention, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
  • Evidence-based Medicine Center, Fudan University, Shanghai, 200032, China.
  • Department of Oncology, Huadong Hospital, Fudan University, Shanghai, 200040, China.

ORCID-Profile: Xiaojing Xu, Minzhi Lv, Xi Tang, Tianshu Liu

Förderung

  • CSCO Clinical Oncology Research Foundation
  • Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • National Nature Science Foundation of China

Zitieren

APA

Xu, X., Lv, M., Ai, L., Wang, Q., Cui, Y., Li, W., Liu, Q., Tang, X., Chen, X., Yu, S., Guo, M., Yu, Y., & Liu, T. (2026). Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag385

Vancouver

Xu X, Lv M, Ai L, Wang Q, Cui Y, Li W, et al. Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag385

BibTeX
@article{Xu2026,
  author = {Xu, Xiaojing and Lv, Minzhi and Ai, Luoyan and Wang, Qing and Cui, Yuehong and Li, Wei and Liu, Qing and Tang, Xi and Chen, Xi and Yu, Shan and Guo, Mengzhou and Yu, Yiyi and Liu, Tianshu},
  title = {Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {11},
  doi = {10.1093/oncolo/oyag385}
}
Kostenlos starten →